Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A C Marrast

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Transplantation Proceedings|August 1, 1995
Management of ovarian cancer in the renal transplant recipient with cyclophosphamide used as an immunosuppressive and antineoplastic agentF Vincent, M Michel, A C Marrast, et al.
Transplantation Proceedings|August 1, 1997
Pregnancy in kidney transplantation: past and present experienceL Bererhi, J Bedrossian, F Metivier, et al.
Clinical Nephrology|August 31, 2006
Long-term administration of enteric-coated mycophenolate sodium (EC-MPS; myfortic) is safe in kidney transplant patientsM Salvadori, H Holzer, G Civati, et al.
Clinical Nephrology|August 31, 2006
Long-term safety and efficacy after conversion of maintenance renal transplant recipients from mycophenolate mofetil (MMF) to enteric-coated mycophenolate sodium (EC-MPA, myfortic)K Budde, G Knoll, J Curtis, et al.
Transplantation Proceedings|October 1, 1996
Renal transplantation between spousesP Cloix, A C Marrast, N Lefrançois, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Transplantation Proceedings|August 1, 1995
Management of ovarian cancer in the renal transplant recipient with cyclophosphamide used as an immunosuppressive and antineoplastic agentF Vincent, M Michel, A C Marrast, et al.
Transplantation Proceedings|August 1, 1997
Pregnancy in kidney transplantation: past and present experienceL Bererhi, J Bedrossian, F Metivier, et al.
Clinical Nephrology|August 31, 2006
Long-term administration of enteric-coated mycophenolate sodium (EC-MPS; myfortic) is safe in kidney transplant patientsM Salvadori, H Holzer, G Civati, et al.
Clinical Nephrology|August 31, 2006
Long-term safety and efficacy after conversion of maintenance renal transplant recipients from mycophenolate mofetil (MMF) to enteric-coated mycophenolate sodium (EC-MPA, myfortic)K Budde, G Knoll, J Curtis, et al.
Transplantation Proceedings|October 1, 1996
Renal transplantation between spousesP Cloix, A C Marrast, N Lefrançois, et al.
Pageof 1